<DOC>
	<DOCNO>NCT00527215</DOCNO>
	<brief_summary>Multicenter , open label single arm study 140 subject CRI currently receive SC darbepoetin alfa every week receive darbepoetin alfa every 4 week 24 week . Upon enrollment study , subject receive darbepoetin alfa every 4 week 24 week . The initial dose equivalent subject 's total dose month precede enrollment . Doses may titrate maintain Hb concentration target range .</brief_summary>
	<brief_title>Phase 2 Study Darbepoetin Alfa Extended Dosing</brief_title>
	<detailed_description />
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Greater equal 18 year age CRI creatinine clearance great 15 less 40 mL/min Stable every week darbepoetin alfa SC least 6 week Hb value screen / baseline 10.0 12.0 g/dL Serum B12 folate level low limit normal iron replete Receiving renal replacement therapy Uncontrolled hypertension Hyperparathyroidism Major surgery , active inflammatory disease , receive antibiotic , HIVpositive Current malignancy Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>